[go: up one dir, main page]

DE60006100D1 - Lang wirkende insulinotrope peptide - Google Patents

Lang wirkende insulinotrope peptide

Info

Publication number
DE60006100D1
DE60006100D1 DE60006100T DE60006100T DE60006100D1 DE 60006100 D1 DE60006100 D1 DE 60006100D1 DE 60006100 T DE60006100 T DE 60006100T DE 60006100 T DE60006100 T DE 60006100T DE 60006100 D1 DE60006100 D1 DE 60006100D1
Authority
DE
Germany
Prior art keywords
peptides
angiogenic
modified
conjugates
insulinotrope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60006100T
Other languages
English (en)
Other versions
DE60006100T2 (de
Inventor
P Bridon
Archeveque Benoit L
M Ezrin
Darren L Holmes
Anouk Leblanc
Pierre Serge St
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONJUCHEM BIOTECHNOLOGIES INC., MONTREAL, QUEBEC,
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Publication of DE60006100D1 publication Critical patent/DE60006100D1/de
Application granted granted Critical
Publication of DE60006100T2 publication Critical patent/DE60006100T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
DE60006100T 1999-05-17 2000-05-17 Lang wirkende insulinotrope peptide Expired - Lifetime DE60006100T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US134406P 1999-05-17
US15978399P 1999-10-15 1999-10-15
US159783P 1999-10-15
PCT/US2000/013563 WO2000069911A1 (en) 1999-05-17 2000-05-17 Long lasting insulinotropic peptides

Publications (2)

Publication Number Publication Date
DE60006100D1 true DE60006100D1 (de) 2003-11-27
DE60006100T2 DE60006100T2 (de) 2004-07-01

Family

ID=26832298

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60006100T Expired - Lifetime DE60006100T2 (de) 1999-05-17 2000-05-17 Lang wirkende insulinotrope peptide

Country Status (16)

Country Link
US (4) US6329336B1 (de)
EP (1) EP1180121B9 (de)
JP (5) JP4115671B2 (de)
CN (1) CN1191273C (de)
AT (1) ATE252601T1 (de)
AU (1) AU754770B2 (de)
BR (1) BR0010750A (de)
CA (2) CA2363712C (de)
DE (1) DE60006100T2 (de)
DK (1) DK1180121T3 (de)
EA (1) EA003922B1 (de)
ES (1) ES2209885T3 (de)
NO (1) NO20015584L (de)
PT (1) PT1180121E (de)
SI (1) SI1180121T1 (de)
WO (1) WO2000069911A1 (de)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6447772B1 (en) * 1999-10-01 2002-09-10 Klaire Laboratories, Inc. Compositions and methods relating to reduction of symptoms of autism
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
WO2002062844A2 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
EP1360202B1 (de) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
DK1427750T3 (da) * 2001-08-30 2011-02-14 Biorexis Pharmaceutical Corp Modificerede transferrin-fusionsproteiner
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
HRP20040343A2 (en) * 2001-10-18 2005-08-31 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP2277889B1 (de) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusionsproteine von Albumin und Interferon beta
CA2484556A1 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003213047A1 (en) * 2002-02-13 2003-09-04 Medbridge, Inc. Protein carrier system for therapeutic oligonucleotides
JP4417113B2 (ja) * 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
AU2003239478A1 (en) * 2002-06-04 2003-12-22 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
EP1837031B1 (de) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
ATE432289T1 (de) 2002-07-04 2009-06-15 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
AU2003262886A1 (en) * 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP1542718B1 (de) * 2002-09-24 2015-11-11 Dong Xie Von peptiden abstammende fusions-inhibitoren gegen hiv infektionen
AU2003268621B2 (en) 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2509755A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
BRPI0408978B8 (pt) * 2003-04-08 2021-07-27 Novo Nordisk As processos para regenerar uma fase estacionária cromatográfica
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
WO2004094823A2 (en) 2003-04-23 2004-11-04 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
CN1812983A (zh) 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
CN1964989B (zh) * 2003-07-25 2012-02-01 康久化学生物技术公司 长效胰岛素衍生物及其方法
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
CA2535619A1 (en) * 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
EP1663278A4 (de) * 2003-08-28 2009-07-29 Biorexis Pharmaceutical Corp Epo mimetika-peptide und fusionsproteine
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
WO2005021026A2 (en) * 2003-08-29 2005-03-10 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US7214190B1 (en) 2003-09-09 2007-05-08 Kitchener Clark Wilson Apparatus and method for noninvasive monitoring of analytes in body fluids
AU2004298425A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 analogues linked to albumin-like agents
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
AU2005207870B2 (en) * 2004-01-30 2010-08-19 Waratah Pharmaceuticals, Inc. The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels
CA2554089C (en) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
GEP20094679B (en) * 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
PT2100904E (pt) * 2004-04-23 2010-09-24 Conjuchem Biotechnologies Inc Fase sólida para utilização num método para a purificação de conjugados de albumina
CN1318587C (zh) * 2004-04-30 2007-05-30 成都芝田生物工程有限公司 酰胺化Exendin－4多肽的重组制备方法
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
JP5107713B2 (ja) * 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
EP1799710A2 (de) 2004-10-07 2007-06-27 Novo Nordisk A/S Glp-1 verbindungen mit verlängerter wirkdauer
US20080125361A1 (en) * 2004-11-12 2008-05-29 Novo Nordisk A/S Stable Formulations Of Peptides
US7872124B2 (en) * 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8716221B2 (en) * 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
CN101309689B (zh) * 2005-09-14 2012-10-10 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
PE20070622A1 (es) * 2005-09-14 2007-08-22 Takeda Pharmaceutical Administracion de inhibidores de dipeptidil peptidasa
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CN101360723A (zh) * 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
WO2007051987A1 (en) * 2005-11-01 2007-05-10 Activotec Spp Limited Insulinotropic compounds and uses thereof
SG166829A1 (en) 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
US20080280328A1 (en) * 2005-11-18 2008-11-13 Novozymes A/S Glucoamylase Variants
JP2009520469A (ja) * 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド アルブミンと治療薬との前もって形成された抱合体の産生のための方法
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
EP1987052B1 (de) * 2006-02-08 2011-04-27 Lonza AG Synthese von glucagon-ähnlichen peptiden
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
ES2566058T3 (es) 2006-03-30 2016-04-08 Valeritas, Inc. Dispositivo de suministro de fluidos de múltiples cartuchos
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
KR100886783B1 (ko) 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
WO2008011446A2 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
CA2658654A1 (en) * 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
PE20080840A1 (es) * 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
DK2073810T3 (da) * 2006-09-13 2011-10-31 Takeda Pharmaceutical Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
WO2008154619A1 (en) * 2007-06-12 2008-12-18 Smithkline Beecham Corporation Methods for detecting protein in plasma
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
JP2010538049A (ja) 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス 切断型ｇｌｐ−１誘導体及びその治療的使用
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
DK2205624T3 (da) * 2007-10-27 2017-01-02 Corden Pharma Colorado Inc Insulinotropisk peptidsyntese under anvendelse af faststof- og opløsningsfasekombinationsteknikker
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
MX337038B (es) 2008-06-17 2016-02-10 Univ Indiana Res & Tech Corp Co-antagonistas de receptor de glucagon/glp-1.
EP2300035B1 (de) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gemischte agonisten auf gip-basis zur behandlung von stoffwechselerkrankungen und fettsucht
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
TW201012829A (en) * 2008-09-22 2010-04-01 Ipsen Mfg Ireland Ltd Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373681B1 (de) 2008-12-10 2017-01-18 Glaxosmithkline LLC Pharmazeutische zusammensetzungen enthaltend albiglutide
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
AU2010218139B2 (en) 2009-02-25 2012-11-01 Merck Sharp & Dohme Corp. Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast Pichia pastoris
EP2416797A4 (de) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc Amylinagonistverbindungen für säuger mit östrogenmangel
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
JP5932642B2 (ja) * 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
KR101525473B1 (ko) * 2009-09-30 2015-06-03 고쿠리츠 다이가쿠 호진 교토 다이가쿠 췌도 이미징용 분자 프로브 및 그 사용
US20120264685A1 (en) 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2011058083A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
AU2010321587A1 (en) 2009-11-23 2012-06-07 Amylin Pharmaceuticals, Inc. Polypeptide Conjugate
KR101813595B1 (ko) 2010-01-22 2017-12-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 장기적 생체 내 효능을 갖는 성장 호르몬
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
MX2012009802A (es) 2010-02-24 2012-09-12 Merck Sharp & Dohme Metodo para incrementar la ocupacion del sitio de n-glucosilacion en glucoproteinas terapeuticas producidas en pichia pastoris.
RU2559320C2 (ru) * 2010-03-26 2015-08-10 Ново Нордиск А/С Новые аналоги глюкагона
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
AU2011247452B2 (en) 2010-04-27 2016-03-17 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3450568A3 (de) * 2011-03-04 2019-04-24 Intrexon Corporation Vektoren für bedingte proteinexpression
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ME02816B (me) 2011-06-22 2018-01-20 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
KR101357117B1 (ko) * 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
HRP20151068T1 (hr) 2011-08-29 2016-01-01 Sanofi-Aventis Deutschland Gmbh Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013029279A1 (zh) * 2011-09-03 2013-03-07 深圳市健元医药科技有限公司 新的glp-ⅰ类似物及其制备方法和用途
CN102286092B (zh) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
MX2014005351A (es) 2011-11-03 2014-05-28 Zealand Pharma As Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
TR201903918T4 (tr) 2012-03-22 2019-04-22 Novo Nordisk As Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
WO2013163162A1 (en) * 2012-04-24 2013-10-31 Amylin Pharmaceuticals, Llc Site-specific enzymatic modification of exendins and analogs thereof
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
EP2863895B1 (de) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablettenformulierung enthaltend ein peptid und einen adsorptionsvermittler
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
US20140051834A1 (en) 2012-06-21 2014-02-20 Hoffmann-La Roche, Inc. Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function
IN2015DN00544A (de) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
SI2956476T1 (sl) 2013-02-18 2020-03-31 Vegenics Pty Limited Molekule za vezavo na ligande in uporabe le-teh
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
CN104650212A (zh) * 2013-03-15 2015-05-27 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
CN104592380A (zh) * 2013-03-15 2015-05-06 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
WO2014161835A1 (en) * 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
RU2671406C2 (ru) 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
ES2688708T3 (es) 2013-10-17 2018-11-06 Zealand Pharma A/S Análogos de glucagón acilados
EP3065767B1 (de) 2013-11-06 2020-12-30 Zealand Pharma A/S Zweifach-gip-glp-1-agonistenverbindung und verfahren
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3082847A1 (de) 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Fusionspolypeptide aus lipidiertem inkretin-rezeptor-ligand und human-immunoglobulin-fc-region
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604710XA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
RU2016132340A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP3307326B9 (de) 2015-06-15 2021-02-24 Angiochem Inc. Verfahren zur behandlung von leptomeningealer karzinomatose
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
AU2016371021B2 (en) 2015-12-17 2020-04-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
ES2968038T3 (es) 2015-12-23 2024-05-06 Univ Johns Hopkins Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN108070030B (zh) * 2016-11-17 2023-06-23 江苏豪森药业集团有限公司 洛塞那肽及其类似物的制备方法
SG11201903938XA (en) 2016-12-09 2019-05-30 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
US10905750B2 (en) 2017-11-10 2021-02-02 Donald J. Davidson GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
IL320142A (en) 2018-10-11 2025-06-01 Intarcia Therapeutics Inc Human amylin analog polypeptides and methods of use
CN109400695B (zh) 2018-10-31 2020-06-30 中南大学湘雅医院 一种多肽的修饰方法及应用
CN110183531A (zh) * 2019-05-17 2019-08-30 河北常山生化药业股份有限公司 一种艾本那肽前体的制备方法
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物
US20230158165A1 (en) * 2020-03-27 2023-05-25 Epivax, Inc. Tregitope constructs useful in the prevention and treatment of type 1 diabetes
AU2023353057A1 (en) 2022-09-30 2025-05-01 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN115819493A (zh) * 2022-11-16 2023-03-21 河北常山生化药业股份有限公司 一种多肽固相合成方法
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
KR102743491B1 (ko) 2023-08-01 2024-12-17 (주)인벤티지랩 세마글루타이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 마이크로 입자 및 이의 제조 방법
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) * 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4423034A (en) * 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
EP0578728B1 (de) 1991-04-05 1998-07-01 Genentech, Inc. PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa
CZ315594A3 (en) 1992-06-15 1995-07-12 Pfizer Peptide of glucagon type, insulinotropic derivatives, process of their preparation, pharmaceutical composition containing such compounds and use
EP0602290B1 (de) 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
MX9605109A (es) 1994-04-26 1997-08-30 Childrens Medical Center Angiostatina y metodo de uso para la inhibicion de angiogenesis.
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5854221A (en) 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
CZ298612B6 (cs) 1995-12-13 2007-11-21 The Children's Medical Center Corporation Inhibitor proliferace endothelových bunek a jeho použití
WO1997025074A2 (en) 1996-01-12 1997-07-17 Redcell Canada, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
ID17252A (id) 1996-04-29 1997-12-11 Akzo Nobel Nv Proses pembuatan obyek yang terbuat dari selulosa
HU224827B1 (hu) 1996-05-03 2006-02-28 Abbott Lab Új antiangiogén peptidek, azokat kódoló polinukleotidok, és eljárások angiogenezis gátlására
US5801146A (en) 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
JP2000516912A (ja) 1996-06-05 2000-12-19 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング エキセンジン類似体、それらの製造方法およびそれらを含有する製剤
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
KR100556067B1 (ko) 1996-08-30 2006-03-07 노보 노르디스크 에이/에스 지엘피 - 1 유도체
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5864372A (en) 1996-12-10 1999-01-26 United Microelectronics Corporation Apparatus for implementing a block matching algorithm for motion estimation in video image processing
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
CA2283834A1 (en) 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
CA2295925A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
PT1019077E (pt) 1997-08-08 2008-02-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
EP1056474B1 (de) 1997-11-07 2002-06-12 ConjuChem, Inc. Affinitätsmarkierer für menschliches serum albumin
WO1999024462A2 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Novel conjugates of rgd-containing peptides and endogenous carriers
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
EP1032587B2 (de) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Neuartige exendin agonisten
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US20030170250A1 (en) 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
JP2002512640A (ja) * 1998-03-23 2002-04-23 コンジュケム，インコーポレーテッド 持続性治療薬の局所送達
GB9815505D0 (en) 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
CA2343207A1 (en) 1998-09-09 2000-03-16 U.S. Army Institute Of Surgical Research Nasopharyngeal airway with reflectance pulse oximeter sensor
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
AU2990300A (en) 1999-02-10 2000-08-29 Children's Medical Center Corporation Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
US6465424B1 (en) 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
AU771755B2 (en) 1999-03-18 2004-04-01 Children's Medical Center Corporation Novel antiangiogenic peptides
WO2000061179A1 (en) 1999-04-14 2000-10-19 Karolinska Innovations Ab Kringle domains of plasminogen, capable of modulating angiogenesis in vivo
EP1598365A1 (de) 1999-05-17 2005-11-23 ConjuChem Inc. Schutz von endogenen, therapeutisch wirksamen Peptiden
US7144854B1 (en) * 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
ES2334106T3 (es) 1999-05-17 2010-03-05 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones virales.
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
WO2002062844A2 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
EP1360202B1 (de) 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US20060241019A1 (en) 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
PT2100904E (pt) 2004-04-23 2010-09-24 Conjuchem Biotechnologies Inc Fase sólida para utilização num método para a purificação de conjugados de albumina
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
JP2009520469A (ja) 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド アルブミンと治療薬との前もって形成された抱合体の産生のための方法

Also Published As

Publication number Publication date
JP2003527312A (ja) 2003-09-16
JP4116016B2 (ja) 2008-07-09
EA003922B1 (ru) 2003-10-30
PT1180121E (pt) 2004-03-31
NO20015584D0 (no) 2001-11-15
CN1191273C (zh) 2005-03-02
US6593295B2 (en) 2003-07-15
JP2009001583A (ja) 2009-01-08
EP1180121A1 (de) 2002-02-20
ES2209885T3 (es) 2004-07-01
US7741286B2 (en) 2010-06-22
US20110071082A1 (en) 2011-03-24
SI1180121T1 (en) 2004-04-30
US20020049153A1 (en) 2002-04-25
AU4855500A (en) 2000-12-05
BR0010750A (pt) 2002-02-26
NO20015584L (no) 2002-01-03
CA2501421A1 (en) 2000-11-23
CN1350548A (zh) 2002-05-22
EP1180121B9 (de) 2004-09-08
CA2363712C (en) 2011-05-10
DE60006100T2 (de) 2004-07-01
US20060135428A1 (en) 2006-06-22
US6329336B1 (en) 2001-12-11
AU754770B2 (en) 2002-11-21
DK1180121T3 (da) 2004-03-01
WO2000069911A1 (en) 2000-11-23
ATE252601T1 (de) 2003-11-15
JP2006151986A (ja) 2006-06-15
JP2005255689A (ja) 2005-09-22
JP2009007371A (ja) 2009-01-15
EA200100939A1 (ru) 2002-04-25
EP1180121B1 (de) 2003-10-22
CA2363712A1 (en) 2000-11-23
JP4115671B2 (ja) 2008-07-09

Similar Documents

Publication Publication Date Title
DE60006100D1 (de) Lang wirkende insulinotrope peptide
IN2012DN00520A (de)
TR200002299T2 (tr) Epotilon kompozisyonları.
EP1329458A3 (de) Peptide, die den Blutzuckergehalt senken
WO2006081249A3 (en) Conjugates of biologically active proteins having a modified in vivo half-life
TW200711657A (en) Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
BG105396A (en) Utilisation of dialkylfumarates
AU2378402A (en) Imaging, diagnosis and treatment of disease
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
AU3739500A (en) Protease resistant flint analogs
DE60234858D1 (de) Polyalkylenoxid-Konjugate von thiolhaltigen Arzneistoffen
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
BR9506507A (pt) Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao
TNSN00190A1 (fr) Peptides anti-angiogeniques a action de longue duree
DE69940708D1 (de) Pharmazeutische Zubereitungen zur parenteralen Verabreichung enthaltend Epothilon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CONJUCHEM BIOTECHNOLOGIES INC., MONTREAL, QUEBEC,